Cyclo Therapeutics, Inc. (NASDAQ:CYTH – Get Free Report)’s share price rose 1.4% during trading on Friday . The stock traded as high as $0.85 and last traded at $0.82. Approximately 33,205 shares traded hands during mid-day trading, a decline of 37% from the average daily volume of 52,627 shares. The stock had previously closed at $0.81.
Cyclo Therapeutics Price Performance
The stock’s fifty day simple moving average is $0.67 and its two-hundred day simple moving average is $0.81.
Cyclo Therapeutics Company Profile
Cyclo Therapeutics, Inc, a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease.
Read More
- Five stocks we like better than Cyclo Therapeutics
- 3 Monster Growth Stocks to Buy Now
- MP Materials: Rare Earth Elements Powering the EV Boom
- What is an Earnings Surprise?
- Verizon’s Turnaround Gains Traction: New Highs Are Likely in 2025
- Top Stocks Investing in 5G Technology
- Bloom Energy: Powering the Future With Decentralized Energy
Receive News & Ratings for Cyclo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
